Management of Type 2 Diabetes in Adults at Primary Care Level

Objectives

Improve the length and quality of life of people in South Africa by preventing or delaying type 2 diabetes, achieving early diagnosis and effective long-term management, and reducing premature mortality, disability, complications and emergencies. The guideline forms part of the Diabetes Implementation Strategy, responds to the African Diabetes Declaration and Strategy, and contributes to national non-communicable disease and life-expectancy objectives.[1][2]

• Promote healthy eating, physical activity, weight control, smoking cessation and other lifestyle measures to prevent obesity, intermediate hyperglycaemia and type 2 diabetes, particularly among people at elevated risk.[1][3][4][5]
• Identify diabetes and cardiovascular risk early through focused health-care-based screening, prioritising people with overweight or obesity, metabolic syndrome, family history, previous gestational diabetes, high-risk ethnic backgrounds and other recognised risk factors.[2][6][7][4]
• Provide comprehensive primary-care diabetes management that combines individualised glycaemic, blood-pressure and lipid control with education, self-management, medicines, monitoring and appropriate referral.[1][8][9][10]
• Prevent, detect and manage microvascular and macrovascular complications, including kidney disease, retinopathy, foot disease, cardiovascular disease, periodontal disease and disability.[2][11][12][13][14]
• Support populations requiring tailored care, including older people, pregnant people, people living with HIV, people receiving tuberculosis treatment, people intending to fast, and drivers at risk of hypoglycaemia.[15][16][17][18][14]
• Empower people with diabetes, families and carers to understand diabetes as serious but controllable, to participate actively in care, and to prevent or recognise complications and emergencies.[1][19][20]

Implementation

Deliver organised, person-centred diabetes care through primary-health-care clinics, supported by multidisciplinary teams, standardised protocols, reliable medicines and supplies, patient records, education, audit and referral pathways. Implementation requires collaboration between the National Department of Health, provincial, district and facility managers, other government departments, non-governmental organisations, communities, professional bodies, patients and carers.[1][2][8][14][21]

• Organise clinics around trained chronic-disease personnel, private consultation and group-education space, functioning and calibrated equipment, patient registers with recall systems, legible records, and continuous availability of medicines, insulin, syringes, test strips and other consumables.[7][22][21]
• Confirm diabetes using formal laboratory testing, repeating the same diagnostic test on another day for asymptomatic or uncertain cases; use glycated haemoglobin diagnostically only where quality assurance, standardised assays, affordability and availability permit.[23][6]
• Provide structured initial, routine and annual assessments covering symptoms, medical and family history, lifestyle, psychosocial factors, medication use, hypoglycaemia, weight, blood pressure, feet, eyes, oral health, cardiovascular status and relevant biochemical tests.[24][25]
• Individualise treatment targets and intensify therapy when needed, beginning with lifestyle modification and metformin where appropriate, adding a sulphonylurea and then insulin when glycaemic control remains inadequate, while checking adherence and treatment safety.[9][26][27][28]
• Provide structured diabetes self-management education at diagnosis and reinforce it regularly through trained educators, active learning, culturally and linguistically appropriate materials, family or caregiver involvement, group sessions where suitable, and individual support where required.[19]
• Support adherence through shared treatment planning, motivational interviewing, routine-based reminders, simplified regimens where clinically suitable, clear records, assessment of adverse effects and multimethod adherence review.[20][29][30][31]
• Establish referral and return-referral arrangements for severe metabolic decompensation, pregnancy, advanced complications, renal dysfunction, high-risk foot disease, visual problems, specialist insulin management and other conditions beyond primary-care capacity.[32][28][33][34][15]
• Integrate diabetes care with tuberculosis services by screening people with tuberculosis for diabetes at treatment initiation, investigating tuberculosis symptoms among people with diabetes, monitoring interactions and hyperglycaemia, and maintaining facility infection-control plans.[35][14]
• Monitor clinic performance through regular audits, patient-record reviews and annual assessment of achievement of glycaemia, blood-pressure and lipid targets, alongside completion of designated care processes such as foot, retinal, blood-pressure and glycated-haemoglobin assessments.[7][22]
• Review chronic patients at intervals suited to clinical need, assess progress in blood pressure, glucose, weight and glycated haemoglobin at least quarterly in chronic-care records, and revise interventions when control deteriorates.[24][21]
• Develop nationally agreed process and outcome indicators and data-collection tools for collaborative tuberculosis and diabetes activities; beyond clinical audits and these proposed tools, a comprehensive programme-level reporting, surveillance and accountability framework is not specified.[14][36]
• Resource implementation through sufficient staff time, education capacity, monitoring equipment, medicine supply and referral services. No overall budget, financing mechanism, funding allocation or quantified programme cost is specified.[8][19][21]

Monitoring & Evaluation

Monitoring is primarily embedded in routine clinical care, clinic management and periodic audit rather than in a fully specified national evaluation system. Services are expected to use patient registers, recall systems, legible records, chronic-disease indicators and regular audits to assess whether interventions are implemented and whether care improves glycaemic control and reduces complications.[2][7][22]

• Conduct annual clinic-performance reviews using the number of patients meeting guideline targets for glycaemia, blood pressure and lipids.[22]
• Audit completion of designated care processes, including blood-pressure measurement, glycated haemoglobin testing, foot examination and retinopathy assessment, using checklists and randomly selected patient records; report the proportion of sampled patients receiving all required procedures.[22]
• Review chronic patients at least quarterly through recorded blood pressure, blood glucose, weight and glycated haemoglobin results, identify improvement or deterioration, and revise interventions where necessary.[21]
• Maintain medical histories and patient records, assess service effectiveness and chronic-illness coping skills, and use referral and return-referral arrangements as part of ongoing care management.[8]

Clinical monitoring is structured around initial assessments, follow-up visits and annual reviews. Initial assessment covers symptoms, medical history, complications, medicines, lifestyle, psychosocial factors, physical examination and biochemical testing.[24]Follow-up every three to six months until targets are achieved includes adherence, adverse effects, hypoglycaemia, lifestyle, depression, home monitoring, weight, waist circumference, blood pressure, foot status and glucose control.[24]Annual review is broadly equivalent to the initial assessment, with more frequent testing or examination when abnormalities are found.[24]

• Monitor glycated haemoglobin every three to six months when above target or after treatment change, and individualise targets according to age, risk, hypoglycaemia awareness and prognosis.[25][9]
• Repeat laboratory diagnostic testing on another day for asymptomatic or uncertain diabetes cases, while symptomatic people with unequivocal hyperglycaemia may be diagnosed from one abnormal test.[6]
• Screen for chronic kidney disease with urine albumin-to-creatinine ratio and estimated glomerular filtration rate, repeat abnormal findings within three months, and measure renal function at least annually.[11][33]
• Measure lipids annually when satisfactory, repeat testing after three months when results are unsatisfactory or therapy is initiated, and test every three months while lipid-lowering treatment is being titrated.[37][38]
• Measure blood pressure at every clinic visit and monitor renal function and potassium after starting or titrating an angiotensin-converting enzyme inhibitor.[39][33]

Complication surveillance relies on regular risk assessment, screening, documented findings and referral. Eye care includes examination at type 2 diabetes diagnosis, annual screening for no or minimal retinopathy, visual-acuity testing and urgent ophthalmology referral for sight-threatening disease.[12][34]Foot assessment should be recorded and used to stratify review intervals from annual review for low-risk patients to every one to three months after previous ulceration or amputation.[40]Patients with diabetes should also be assessed for cardiovascular risk factors, metabolic syndrome and chronic complications as part of routine care.[10][37]

• Monitor insulin treatment through fasting glucose, adherence checks, written titration instructions and re-evaluation of the regimen if targets remain unmet within three to six months.[28]
• Monitor admitted patients with hypoglycaemia clinically and through four-hourly blood-glucose testing for 24 to 48 hours, while investigating the cause of each episode.[41]
• Screen people living with HIV who have diabetes risk factors every six months, preferably using fasting plasma glucose, and monitor people receiving tuberculosis treatment for side-effects, drug interactions and hyperglycaemia.[17][14]
• Agree core process and outcome indicators and data-collection tools for collaborative tuberculosis and diabetes activities at national-programme level.[14]
• Audit diabetes education programmes and their effects on outcomes, alongside regular psychological and emotional assessment.[19]

Accountability arrangements are only partly developed in the supplied material. Clinical teams, clinics and national programmes have monitoring responsibilities, but most extracts do not specify standardised indicator definitions, reporting templates, national reporting schedules, independent evaluation arrangements, named accountable institutions or a comprehensive population-surveillance system.[42][14][21]Driving-related provisions create limited individual accountability: medical assessment should document complications, glycaemic control and hypoglycaemia, while the Road Traffic Act requires people aware that they are disqualified by uncontrolled diabetes to surrender their licence within 21 days.[5]

Costing & Financing

No explicit budgets, costed implementation plan, financing source, funding allocation, funding gap, resource-mobilisation mechanism or quantified economic assumption is provided across the supplied extracts.[1][14][21]The material nevertheless identifies substantial resource requirements for organised primary-care delivery, including trained personnel, protocols, clinic space, calibrated equipment, glucose meters, test strips, glycated-haemoglobin capability, patient registers, medicines, insulin, syringes, consumables, education materials and referral capacity.[7][22][8]

• Ensure continuous availability of oral anti-diabetic medicines, insulin, syringes, disposable supplies and other essential medicines, although no associated financial values are specified.[8]
• Consider affordability, local availability, assay standardisation and quality assurance when selecting glycated-haemoglobin or plasma-glucose testing for diagnosis.[6]
• Recognise that foot complications increase healthcare costs and that retinal photography is characterised as effective, acceptable and cost-effective, without quantified costs or savings.[12][34]
• Use small-group diabetes education as the preferred cost-effective delivery option, while retaining individual education where needed and allocating sufficient time and resources for ongoing education.[19]
• Consider long-term prevention interventions in terms of safety, effectiveness, affordability and wider health benefits; metformin is described as relatively low cost for prevention, but no price or programme cost is reported.[5]
• Recognise operational resource needs for adherence support, including potentially longer consultations, patient-language materials, treatment-support programmes and monitoring tools, without monetary estimates.[29][31]

The extracts identify medicines, monitoring supplies, workforce capacity and specialised services as necessary inputs, but do not provide sufficient information to estimate costs, compare financing scenarios, calculate funding gaps or assess affordability at programme level.[20][43][21]